

(F53-4)

- Translation –
Capital Increase Report
Inter Pharma Public Company Limited

Inter Pharma Public Company Limited (“the Company”) would like to report the resolution of the Board of Directors Meeting No. 1/2026, which was convened on March 2, 2026 regarding the capital decrease, capital increase and allocation of newly issued shares, with details as follows:

1. Capital Reduction and Capital Increase:

1.1 Capital Reduction

The Board of Directors' Meeting resolved to propose to the shareholders' meeting to consider and approve of a reduction of the Company's registered capital in the amount of Baht 75,715,127.50 from the existing registered capital of Baht 378,387,365 to a new registered capital of Baht 302,672,237.50 By cancelling 151,430,255 authorized but unissued ordinary shares with a par value of Baht 0.50 per share, which were reserved for the exercise of warrants to purchase the Company's ordinary shares No. 2 (IP-W2) 93,129,515 ordinary shares, additionally reserved for the adjustment of rights of the warrants to purchase the Company's ordinary shares No. 2 (IP-W2) 58,299,187 ordinary shares, and 1,553 remaining shares reserved for the payment of share dividends.

1.2 Capital Increase

The Board of Directors' Meeting resolved to propose to the shareholders' meeting to consider and approve the capital increase of the company of Baht 2,250,000 from the former registered capital of Baht 302,672,237.50 to Baht 304,922,237.50 by issuing 4,500,000 newly issued ordinary shares with a par value of 0.50 Baht per share to allocate to reserve for the exercise of the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) Details as follows:

Capital increase	Category of Shares	No. of Shares	Par Value (Baht per share)	Total (THB)
● Specifying the purpose of utilizing funds	Common Shares	4,500,000	0.50	2,250,000

2. Allocation of New Shares:

2.1 Specifying the Purpose of Utilizing Funds:

Allocated to	No. of Shares	Ratio (new : old)	Sale Price (Baht per share)	Subscription and payment period	Remark
Executives and/or Employees' of the Company or its subsidiaries	Not exceeding 4,500,000 shares	Please See details in Enclosure 1	Please See details in Enclosure 1	Please See details in Enclosure 1	Please see Note 2

Remarks: /1 Calculation from the weighted average purchase and sale price of the common shares of the company for the past 15 consecutive days before the company board meeting

/2 Details of the issuance and allocation of the IP ESOP-W1 warrants as per enclosure 1 the summary of the Stock Warrant

2.2 The Company's procedure in case there is remaining fractional shares:

In the event that there are remaining common shares after the exercise of rights under the IP ESOP-W1 as per the terms of the warrant, the company will cancel the remaining issued common shares and proceed with a subsequent reduction of registered capital. Additionally, in the case where any IP ESOP-W1 remains unexercised upon the expiration of the warrants' validity period as per the terms, the company will cancel the remaining IP ESOP-W1.

3. Schedule for a Shareholders' Meeting to approve the capital increase and share allotment:

The 2026 Annual General Meeting of Shareholders on April 27, 2026, at 2.00 P.M. via an electronic channel (E-Meeting). The record date of the Shareholders obtaining entitlement to attend the Meeting on March 17, 2026.

4. Approval of the capital increase/share allotment by relevant governmental agency and conditions thereto:

4.1 The Company will proceed with the reduction and increase of its registered capital and amend the Memorandum of Association with the Department of Business Development, Ministry of Commerce, within 14 days from the date of approval by the shareholder's meeting. Additionally, the company will register the change in paid-up capital with the Department of Business Development, Ministry of Commerce, within 14 days from the date of receiving payment for the shares each time a IP ESOP-W1 is exercised.

4.2 The Company will apply to the Stock Exchange of Thailand (the "SET") for approval to list the ordinary shares arising from the exercise of IP ESOP-W1 as listed securities and to have such shares traded on the SET, on which the Company's ordinary shares are currently traded.

5. Objectives of the capital increase and plans for utilizing the increased capital:

Purpose of the capital increase: To support the conversion of IP ESOP-W1

Usage of capital increase: To use the funds received from the exercise of the IP ESOP-W1 as working capital

6. Benefits which the Company will receive from the capital increase and share allotment:

1. To motivate executives and employee with outstanding performance and commitment to achieve the Company's long-term business goals.
2. To be a long-term retention program for skilled personnel in key business areas.
3. To raise working capital assuming the warrants are exercised.

7. Benefits that shareholders will receive from the capital increase and share allotment:

7.1 Dividend Policy: The Company has a policy to pay dividends to its shareholders at a rate of not less than 50% of its net profit after corporate income tax and after all statutory reserves as required by law, based on the Company's separate financial statements. The payment of dividends shall be subject to cash flow, the adequacy of working capital for business operations, investment plans, repayment of loans, terms and conditions of agreements to which the Company is bound, legal restrictions, and other future necessities and appropriateness.

7.2 The executives and/or employees of the Company or its subsidiaries who hold the IP ESOP-W1 warrants shall be entitled to receive dividends from the Company's operations only after they have exercised their rights under the warrants to subscribe for the Company's ordinary shares and have been duly registered as shareholders of the Company.

8. Other details necessary for shareholders to approve the capital increase/share allotment

-None-

9. Schedule of action if the Board of Directors passes a resolution approving the capital increase and allotment of new shares:

No.	Procedures of the capital increase	Estimated time
1.	The Board of Directors' Meeting	March 2, 2026
2.	Record Date to determine the shareholders who have the rights to attend the Annual General Meeting of Shareholders for the year 2026	March 17, 2026

No.	Procedures of the capital increase	Estimated time
3.	The 2026 Annual General Meeting of Shareholders	April 27, 2026
4.	Registering to reduce the Company capital and amendment of the Memorandum of Association to be consistent with the reduction of the Company's registered capital with Department of Business Development Ministry of Commerce	Within 14 days from the date of approval from the shareholder's meeting
5.	Registering to increase the Company capital and amendment of the Memorandum of Association to be consistent with the increase of the Company's registered capital with Department of Business Development Ministry of Commerce	Within 14 days from the date of approval from the shareholders' meeting.

The Company hereby certifies that the information contained in this report form is true and complete in all respects.

Signed-Signature-.....-Signature-..... Authorized Director
 (Dr. Trinawat Thanitnithiphan) (Ms. Napaporn Dechakarat)